This research study is being performed to see if women diagnosed with early preterm
Hemolysis, Elevated Liver Enzymes, Low Platelets (HELLP) syndrome (estimated gestational ages
of 23-30 weeks) benefit from a medication called eculizumab (ECU). This drug blocks a part of
the immune system called complement. By blocking this part of the immune system, eculizumab
may stop or reverse the progression of the HELLP syndrome disease. The investigators will
also look to see if this drug is effective and benefits both the mother and fetus.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)